Blog | Veristat, The Science-First CRO

2 min read

Strengthening Opportunities for Growth in the European Region

1 min read

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the...

Bold Thinking that Delivers Results for RNA Therapies

Current advances in RNA-based therapies hold substantial promise in treating and preventing many human diseases and disorders through curing the disease, rather than treating the symptomology like traditional therapeutics.

2 min read

On-Demand Webinar: Decentralized Trial Solutions for Complex Clinical Trials

Decentralized clinical trials (DCTs) are becoming increasingly popular to optimize patient engagement and retention. At the same time, making DCTs a successful reality for the most complex studies is considered difficult given the many logistical and...

5 min read

Laying the Groundwork to Measure the Impact of Decentralized Clinical Trials (DCTs)

The Tufts CSDD Roundtable took place in November, and on behalf of Veristat, I was honored to participate in this invite-only program. It is part of our company’s DNA to stay ahead of the driving forces in the industry so that we can best serve as a...

1 min read

Is it Possible to Gain Regulatory Approval Following a Single-Arm Study?

In this case study example - yes.

Veristat developed a thorough regulatory submission strategy and novel efficacy endpoint for the treatment of an ultra-rare and aggressive hematologic malignancy that led to FDA and EMA approval following a single-arm...

4 min read

Planning the Way Forward in Neurodegenerative Disease Studies

Clinical trials involving gene therapies for the treatment of Central Nervous System (CNS) indications are some of the more complex in the field of gene and cell therapy (G&CT) development. During the lockdown, the Food and Drug Administration (FDA)...